Robin Shah, chief commercial officer of OneOncology, addresses the role that biosimilars have in community oncology.
Transcript
We're really excited about some of the shifts in biosimilars. And this comes from a number of things. The first is the advancement of science in this space really is going to pave the future for opportunities for new drug classes to come into community oncology and oncology in general.
The second is, as we go into value-based arrangements, the important thing that comes with value-based is total cost of care. And with the introduction of biosimilars and a lot of the new relationships that OneOncology is going into, we're going to really be able to reduce the total cost of care with all these new agents being introduced to the marketplace.
And as you may have seen from our press release, we've gone into a large partnership on this front. And with the technology that we have, we can now really track and identify where we're complying with biosimilars, and where there are opportunities to shift some of our existing drug agents to new therapies that are coming out.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Dr Fran Gregory Sizes Up the US Adalimumab Market: Will Biosimilars See Success?
September 17th 2023On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.
Dr Joseph Alvarnas Highlights the Current State of the Oncology Biosimilar Market
November 9th 2022Joseph Alvarnas, MD, vice president of government affairs at City of Hope and chief clinical adviser of AccessHope, explains what the recent FDA approvals of Stimufend and Vegzelma, 2 oncology biosimilars, says about the current state of the oncology biosimilar space.
Expert Opinion: What Factors Will Have the Greatest Impact on US Adoption of Humira Biosimilars?
April 12th 2022Jeffrey Casberg, vice president of pharmacy at IPD Analytics, weighs in on the factors he thinks will most affect market share among adalimumab biosimilars when they enter the US market in 2023.